Senologie - Zeitschrift für Mammadiagnostik und -therapie 2020; 17(02): e2
DOI: 10.1055/s-0040-1710600

AXSANA (AXillary Surgery After NeoAdjuvant Treatment): A European prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy

European Breast Cancer Research Association of Surgical Trialists (EUBREAST)
M Banys-Paluchowski
1  Asklepios Klinik Hamburg-Barmbek, Hamburg, Deutschland
E Stickeler
2  Klinik für Gynäkologie und Geburtsmedizin, Uniklinik RWTH Aachen, Aachen, Deutschland
J de Boniface
3  Dept. of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Schweden
4  Dept. of Surgery, Capio St. Göran’s Hospital, Stockholm, Schweden
O Gentilini
5  San Raffaele Hospital Milan, Milano, Italien
M Thill
6  Klinik für Gynäkologie und Gynäkologische Onkologie, Agaplesion Markus Krankenhaus, Frankfurt am Main, Deutschland
S Hartmann
7  Universitäts-Frauenklinik, Klinikum Südstadt Rostock, Rostock, Deutschland
PA Fasching
8  Frauenklinik, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Deutschland
H Huebner
8  Frauenklinik, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Deutschland
N Krawczyk
9  Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
J-U Blohmer
10  Klinik für Gynäkologie mit Brustzentrum der Charité, CCM, Berlin, Deutschland
C Solbach
11  Brustzentrum, Universitätsklinikum Frankfurt, Frankfurt am Main, Deutschland
M Untch
12  Klinik für Gynäkologie und Geburtshilfe, Helios Klinikum Berlin-Buch, Berlin, Deutschland
T Kühn
13  Klinik für Frauenheilkunde und Geburtshilfe, Klinikum Esslingen, Esslingen, Deutschland
› Author Affiliations

Introduction The surgical treatment of the axilla in patients who convert from a clinically positive to a clinically negative node status through neoadjuvant chemotherapy is still unclear. Multiple techniques such as full Axillary Lymph Node Dissection (ALND), Targeted Axillary Dissection (TAD), Targeted Lymph Node Biopsy (TLNB) and Sentinel Lymph Node Biopsy (SLNB) are recommended in international guidelines. So far, no data with respect to outcome (recurrences/survival) or morbidity of the competing procedures are available. In view of the uncertainties related to innovative procedures, further research is urgently needed to safely de-escalate surgical treatment in this patient group.

Materials and methods The EUBREAST study group, with the support of AWOgyn,AGO-B and NOGGO, will initiate an international prospective cohort study (“AXSANA”) including cN+→ycN0 patients treated with different axillary staging techniques according to the standard at their treating institution. The endpoints of the study are 5-year invasive disease-free survival, 3-year axillary recurrence rate and health-related quality of life. AXSANA will be initiated in February 2020, enrolling 3000 patients who will be followed for 5 years.

Results The study concept and enrollment status will be presented at the conference. The frequency of various surgical (ALND, TAD, SLNB) and marking techniques (e.g. clip, radioactive/magnetic seed, ink) in different countries will be reported.

Conclusions Due to high complexity and discordant recommendations, a randomized trial comparing surgical staging techniques is hardly feasible and therefore would not clarify currently open issues within a reasonable timeframe. The prospective international cohort study AXSANA will hopefully help to clarify these issues.

Publication History

Publication Date:
24 June 2020 (online)

© Georg Thieme Verlag KG
Stuttgart · New York